Catalysts / TVRD
Upcoming FDA decisions and readouts we track for Tvardi Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Tvardi Therapeutics (TVRD, listed on Nasdaq). It concerns TTI-101 (Hepatocellular carcinoma (STAT3 inhibitor)).
First on the list: the Phase 1B/2 readout for TTI-101 (Hepatocellular carcinoma (STAT3 inhibitor)), guided by the company to H2 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics TVRD · Nasdaq | TTI-101 | Hepatocellular carcinoma (STAT3 inhibitor) | H2 2026 company guidance |
Phase 1B/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList